CHEK2 and hepatocellular carcinoma: A study showed that RTN3 functions as a new inhibitor and can activate the Chk2/p53 pathway to suppress hepatocellular carcinoma, which provides additional clues for a better understanding of the carcinogenic role of HBV [33].